🔥🔥Presented at #AACR26 by Dr Lyudmila Bazhenova @UCSDCancer impressive Duration of response for 1L
#taletrectenib for ROS1+ NSCLC #TRUST-I/II pooled analysis

N=157
ORR 90%
DoR 49.7mos❗️(4 yrs +)
mOS not reached

concurrent @JCO_ASCO publication 👇🏽
📖 https://t.co/ifoFxaaRmk

@ros1cancer #lcsm